The company shared validation data this week that it said led the FDA to approve use of the test in a new prospective trial of Roche's Tecentriq in NSCLC.
A pair of studies has established a potential role for specific gut bacteria in the progression of MS, suggesting therapeutic targeting of the microbiota as a potential treatment.
Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
Researchers have argued that the facial prediction claims are overblown and serve Human Longevity's financial interests in proprietary genomic databases.
Patients are organizing themselves in groups based on the molecular features driving their tumors to better advocate for themselves, raise money, and influence research.
With the cash, WuXi NextCode will build out its AI and deep learning, seek partnerships in precision medicine and diagnostics, and commercialize genomic tests.
